Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.

BACKGROUND: Memory responses require immune competence. We assessed the influence of priming with AS03-adjuvanted pandemic vaccine (Pandemrix®) on memory responses of HIV patients, kidney recipients (SOT) and healthy controls (HC). METHOD: Participants (HIV: 197, SOT: 53; HC: 156) were enrolled in a prospective study and 390/406 (96%) completed it. All had been primed in 2009/2010 with 1 (HC) or 2 (patients) doses of Pandemrix®, and were boosted with the 2010/2011 seasonal influenza vaccine. Geometric mean titres and seroprotection rates were measured 12 months after priming and 4 weeks after boosting. Primary and memory responses were directly compared in 191 participants (HCW: 69, HIV: 71, SOT: 51) followed during 2 consecutive seasons. RESULTS: Most participants (HC: 77.8%, HIV: 77.6%, SOT: 66%) remained seroprotected at 12 months post-priming. Persisting A/09/H1N1 titers were high in HIV (100.2) and HC (120.1), but lower in SOT (61.4) patients. Memory responses reached higher titers in HIV (507.8) than in HC (253.5) and SOT (136.9) patients. Increasing age and lack of HAART reduced persisting and memory responses, mainly influenced by residual antibody titers. Comparing 2009/2010 and 2010/2011 titers in 191 participants followed for 2 seasons indicated lower post-2010/2011 titers in HC (240.2 vs 313.9), but higher titers in HIV (435.7 vs 338.0) and SOT (136 vs 90.3) patients. CONCLUSIONS: Priming with 2 doses of Pandemrix® elicited persistent antibody responses and even stronger memory responses to non-adjuvanted seasonal vaccine in HIV patients than 1 dose in healthy subjects. Adjuvanted influenza vaccines may improve memory responses of immunocompromised patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT01022905.

Pandemic Influenza Background (PDF 99 KB)

The Presence of highly pathogenicH5N1 avian influenza has been confirmed in birds in Turkey, Romania, Russia and Kazakhstan. There have been a total of 4 confirmed cases of human infection in Eastern/South Eastern Turkey that has resulted in 2 deaths. Background Avian influenza naturally circulates in wild waterfowl such as ducks and geese often causing little or no symptoms. Many other bird species are susceptible to infection with these influenza viruses and in many of these species it may cause severe disease associated with high mortality. Outbreaks associated with high bird mortality are called Highly Pathogenic Avian Influenza (HPAI) to distinguish them from less pathogenic influenza. In January 2004 avian influenza in poultry was confirmed in Vietnam. Subsequently, there have been very substantial outbreaks of avian influenza associated with high mortality affecting poultry in various countries throughout Asia including Vietnam, Thailand, China, Malaysia, Mongolia, North & South Korea, Cambodia, Indonesia, Laos and Japan. These outbreaks are caused by H5N1 subtype of influenza A virus, the same subtype (but not identical to the virus) that caused the outbreak in Hong Kong in 1997. åÊ

Influenza vaccination and humoral alloimmunity in solid organ transplant recipients.

Annual influenza vaccination is recommended in solid organ transplant (SOT) recipients. However, concerns have been raised about the impact of vaccination on antigraft alloimmunity. We evaluated the humoral alloimmune responses to influenza vaccination in a cohort of SOT recipients between October 2008 and December 2011. Anti-HLA antibodies were measured before and 4-8 weeks after influenza vaccination using a solid-phase assay. Overall, 169 SOT recipients were included (kidney = 136, lung = 26, liver = 3, and combined = 4). Five (2.9%) of 169 patients developed de novo anti-HLA antibodies after vaccination, including one patient who developed donor-specific antibodies (DSA) 8 months after vaccination. In patients with pre-existing anti-HLA antibodies, median MFI was not significantly different before and after vaccination (P = 0.73 for class I and P = 0.20 for class II anti-HLA antibodies) and no development of de novo DSA was observed. Five episodes of rejection (2.9%) were observed within 12 months after vaccination, and only one patient had de novo anti-HLA antibodies. The incidence of development of anti-HLA antibodies after influenza vaccination in our cohort of SOT recipients was very low. Our findings indicate that influenza vaccination is safe and does not trigger humoral alloimmune responses in SOT recipients.

Influenza Pandemic Preparedness Plan

Click here to download PDF

Influenza Pandemic Preparedness in Ireland Joint Assessment Report 2007

Influenza Pandemic Preparedness in Ireland Joint Assessment Report 2007 Evaluating the readiness of the European Union and its Member States for influenza are integral components of the overall process of improving overall pandemic preparedness in Europe. A starting point for improving pandemic preparedness was a workshop on preparedness planning organized jointly by the European Commission (EC) and WHO EURO in Luxembourg, March 2005. Click here to download PDF 471kb

National Pandemic Influenza Plan

National Pandemic Influenza Plan The purpose of this document is to tell you about pandemic influenza (flu), to explain what the Government and the health services are doing to prepare for a possible pandemic and most importantly, to advise you what you need to do if there is a pandemic. Click here to download PDF 614kb

Surveillance of influenza in Northern Ireland 2010-11

This report describes influenza activity in Northern Ireland in the 2010-11 winter flu season period.

Surveillance of influenza in Northern Ireland 2012-2013

The 2012/13 influenza season started earlier than in 2011/12; however it lasted longer, with GP consultation rates being elevated for approximately four months. Clinical indices began to increase in late December and peaked in early January, with the only two instances of community syndromic indicators exceeding the baseline threshold occurring in this month. GP influenza-like illness consultation rates in 2012/13 were higher than those in the 2011/12 season for the majority of the season but remained low overall.Overall no one age-group appeared predominantly affected; however, older adults predominated during the peak period, with rates increasing in children during February. Rates for those aged 65 and over increased late in the season, and this was associated with influenza outbreaks in care homes for the elderly.

Surveillance of Influenza in Northern Ireland 2013-2014

�The 2013/14 influenza season started later than in 2012/13, it did not last as long and was noted at generally lower levels throughout than the previous season. Clinical indices began to increase in early January and peaked in mid-March, with community syndromic indicators not exceeding the baseline threshold at any time during the season. GP influenza-like illness consultation rates in 2013/14 were lower than those in the 2012/13 season for the majority of the season and remained low overall.Overall no one age group appeared predominantly affected with rates fluctuating throughout the season. The highest rate overall however was noted among the youngest age group during the peak period.

Seasonal influenza - Questions and answers for registered healthcare practitioners

This document gives advice and guidance for registered healthcare professionals on the 2015/16 seasonal influenza vaccination programme for children.

Surveillance of Influenza in Northern Ireland 2014-2015

The 2014/15 influenza season was characterised by moderate levels of influenza activity.� Primary care consultation rates were higher than in 2013/14 for the majority of the season, although still low overall.� Activity seen in other surveillance was also higher than in 2013/14 year, and showed that the severity and impact of influenza was greater in 2014/15 and affected older age groups most frequently, with more reported respiratory outbreaks, patients with confirmed influenza admitted to Intensive Care Units/High Dependency Units and excess mortality in those over 65 years of a

Impact of anti-T cell therapy in the immunogenicity of seasonal influenza vaccine in kidney transplants recipients

1. Mise en perspective de l'étude La grippe est une cause importante de morbidité et de mortalité après la transplantation d'organe. Bien que la principale stratégie de prévention de la grippe après la transplantation d'organes soit l'administration du vaccin antigrippal annuel, l'immunogénicité de ce vaccin chez les greffés d'organe n'est pas optimale. Nous avons effectué une étude prospective pour évaluer l'influence de la thérapie d'induction sur l'immunogénicité du vaccin de la grippe. 2. Méthodes Nous avons comparé la réponse au vaccin de la grippe chez deux groupes de greffés rénaux en fonction de la thérapie d'induction reçu (thymoglobulin vs basiliximab). Le taux des anticorps ont étés mesurés par inhibition de l'hémagglutination (HI). La réponse au vaccin (taux de séroconversion) a été définie comme l'augmentation > 4 fois du taux d'anticorps (immunoglobulines) et ceci a été notre outcome primaire. 3. Résultats Soixante transplantés rénaux ont été inclus dans l'étude (thymoglobuline=22, basiliximab=38). Les patients dans le group traité par thymoglobuline étaient plus âgés (p=0.16), avaient des valeurs de créatinine plus élevés (p=0.16) et avaient étés transplanté auparavant (p=0.02). Aucune différence n'a été mise en évidence au niveau de taux des immunoglobulines pour les 3 souches virales entre les 2 groupes (p=0.69 pour H INI, p=0.56 pour H3N2, p=0.7 pour Influenza Β). Le taux de séroconversion à au moins une souche virale a été de 68 % pour le groupe thymoglobuline et de 73% pour le groupe basiliximab (p=0.77). 4. Conclusion Aucune différence significative n'a été démontré dans l'immunogénicité du vaccin de la grippe dans les transplantés rénaux ayant reçu soit du thymoglobuline soit du basiliximab comme traitement d'induction.

The epidemiology and antigenic characterization of influenza viruses isolated in Curitiba, South Brazil

Several studies conducted all over the world have reported that the influenza virus is associated with great morbidity and mortality rates. In this study, we analyzed the incidence of the influenza virus between 2000 and 2003 in Curitiba. We studied 1621 samples obtained from outpatients and hospitalized patients of both sexes and all ages. The study was conducted at the local primary care health units (outpatients) and at the tertiary care unit (hospitalized) of the General Hospital of the Federal University in the state of Paraná, Brazil. Nasopharyngeal aspirates and, eventually, bronchoalveolar lavage were assayed for the presence of viral antigens, either by indirect immunofluorescence or cell culture. Of the samples studied, 135 (8.3%) were positive for influenza virus, and of those, 103 (76.3%) were positive for type A and 32 (23.7%) for type B. Additionally, positive samples were analyzed by reverse transcription followed by polymerase chain reaction and subtypes H1 and H3 were identified from this group. A high incidence of positive samples was observed mainly in the months with lower temperatures. Furthermore, outpatients showed a higher incidence of influenza viruses than hospitalized patients.

La gripe A desde la teoría de la elección racional: propuestas para la toma de decisiones de políticas preventivas

This article is a reflection on the social uncertainty caused by Influenza A and on the consequences that it can have on decision making in health promotion policies. We use concepts and metaphors of the Rational Choice Theory, among them, the “ingratitude effect” or the “distrust effect”, as we analyse how these can become obstacles for the efficiency of prevention policies. Then, we focus on the information asymmetry of the principal-agent relationship, and we propose measures to diminish the “moral risk” that they cause. We finish by advancing some proposals for designing lines and strategies of action in health promotion policies.